Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Inclusion Criteria:

1. Male or female aged 18-60 years.

2. Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2.

3. Chronic HBV infection for ≥ 6 months.

4. On NRTI therapy for ≥ 6 months.

Exclusion Criteria:

1. Any clinically significant chronic or acute medical condition that makes theparticipant unsuitable for participation.

2. Significant liver fibrosis or cirrhosis.

3. History or evidence of drug or alcohol abuse.

4. History of intolerance to SC or IM injection.

5. History of chronic liver disease from any cause other than chronic HBVinfection.

6. History of hepatic decompensation.

7. Contraindications to the use of PEG-IFNα.